Allogene Therapeutics (ALLO) Other Non Operating Income (2019 - 2025)
Historic Other Non Operating Income for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$81000.0.
- Allogene Therapeutics' Other Non Operating Income rose 9279.36% to -$81000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year increase of 7771.29%. This contributed to the annual value of -$3.9 million for FY2024, which is 7802.07% up from last year.
- Allogene Therapeutics' Other Non Operating Income amounted to -$81000.0 in Q3 2025, which was up 9279.36% from -$43000.0 recorded in Q2 2025.
- Over the past 5 years, Allogene Therapeutics' Other Non Operating Income peaked at $2.1 million during Q1 2023, and registered a low of -$6.9 million during Q4 2023.
- In the last 5 years, Allogene Therapeutics' Other Non Operating Income had a median value of -$929000.0 in 2024 and averaged -$1.5 million.
- In the last 5 years, Allogene Therapeutics' Other Non Operating Income plummeted by 65122.41% in 2022 and then surged by 12502.73% in 2023.
- Over the past 5 years, Allogene Therapeutics' Other Non Operating Income (Quarter) stood at -$1.8 million in 2021, then plummeted by 101.27% to -$3.6 million in 2022, then crashed by 90.65% to -$6.9 million in 2023, then soared by 71.85% to -$2.0 million in 2024, then surged by 95.85% to -$81000.0 in 2025.
- Its Other Non Operating Income stands at -$81000.0 for Q3 2025, versus -$43000.0 for Q2 2025 and $92000.0 for Q1 2025.